About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, November 7th, 2017

The QualityStocks
Daily Stock List


Sun BioPharma, Inc. (SNBP)

OTC Picks, Hot Shot Stocks, Wall Street Resources, Beacon Equity Research, Greenbackers, CoolPennyStocks, AheadoftheBulls, AllPennyStocks, TheStockWizards.net, The Dean, FeedBlitz, MicrocapVoice, Today's Financial News, HotPennyStocksNow, Otcstockexchange, HotOTC, and Lebed.biz reported earlier on Sun BioPharma, Inc. (SNBP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Sun BioPharma, Inc. is a biopharmaceutical company headquartered in Waconia, Minnesota. The Company is developing disruptive therapeutics for the treatment of patients with pancreatic diseases. A clinical-stage biopharmaceutical company, Sun BioPharma’s development programs target diseases of the pancreas, including pancreatic cancer and pancreatitis. Sun BioPharma lists on the OTCQB.

The Company has scientific collaborations with pancreatic disease experts at Cedars Sinai Medical Center in Los Angeles, California; the University of Miami; the University of Florida; the Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre and the Box Hill Hospital in Melbourne, Australia, and the Ashford Cancer Centre in Adelaide, Australia.

Sun BioPharma’s initial product candidate is SBP-101. This product is for the treatment of patients with pancreatic cancer. Mr. Ray Bergeron, Ph.D. Distinguished Professor Emeritus, University of Florida invented SBP-101. The Company’s plan is to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma, which is the most common type of pancreatic cancer.

SBP-101 is a first-in-class, proprietary, polyamine compound. The design of it is to exert therapeutic effects in a mechanism specific to the pancreas. Sun BioPharma originally licensed SBP-101 from the University of Florida in 2011.

The molecule has been demonstrated to be highly effective in human pancreatic cancer models. It has shown superior activity to existing Food and Drug Administration (FDA) approved chemotherapy agents. In addition, combination therapy potential has been demonstrated for pancreatic cancer.

Furthermore, the Company’s SBP-102 is now in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. Also, Sun BioPharma’s SBP-103 is now in non-clinical exploratory evaluation.

In October, Sun BioPharma announced the successful completion of patient enrolment in its Phase 1a dose escalation safety study using SBP-101 for patients with previously treated locally advanced or metastatic pancreatic ductal adenocarcinoma (PDA). Upon reviewing data from the sixth and final cohort of patients, and data from all 29 patients enrolled in the study, the Data Safety Monitoring Board (DSMB) recommended a safe and well-tolerated dose level of SBP-101 to be used for further clinical development.

Ms. Suzanne Gagnon, MD, Sun BioPharma’s Chief Medical Officer, said, “We are now finalizing the design of a new study to assess SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic PDA. Enrolment is expected to begin in early 2018.”

So far, the best response outcome and survival have been observed in the group of 13 patients who received total cumulative doses of SBP-101 of between 2.5 and 8.0mg/kg.

Sun BioPharma, Inc. (SNBP), closed Tuesday's trading session at $1.50, up 7.91%, on 1,400 volume with 8 trades. The average volume for the last 60 days is 3,959 and the stock's 52-week low/high is $0.55/$4.50.

Rightscorp, Inc. (RIHT)

PennyStocks24, TheNextBigTrade, OTCBB Journal, BestDamnPennyStocks, DSR News, Penny Stock Hub, StocksImpossible, Broad Street, PHUB News, MarketWireStocks, PennyDoctor, PennyPickAlerts, Fortune Stock Alerts, Stock Commander, Pennystocktweeters, Wallstreet Profiler, and Stock News Now reported earlier on Rightscorp, Inc. (RIHT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Rightscorp, Inc. is a foremost provider of data analytics and litigation services, and also copyright infringement protection services to support artists and owners of copyrighted property. The Company’s patent pending digital loss prevention technology focuses on the infringement of digital content. This includes music, movies, software, as well as games. This technology ensures that owners and creators are rightfully paid for Intellectual Property (IP). Rightscorp is based in Santa Monica, California.

Rightscorp uses software that monitors the global Peer‐to‐ Peer (P2P) file sharing networks to seek out and find illegally downloaded digital media. Infringers remit payment to Rightscorp for the copyright infringement and the Company makes payment to the copyright owners.

Rightscorp works closely with its clients to develop programs of education and notice, and as necessary to pursue copyright infringers for their illegal file sharing activities through notifications sent through Internet Service Providers (ISPs). Rightscorp implements existing laws to solve copyright infringements through collecting payments from illegal file sharing activities through the sent notifications.

The Company’s technology identifies copyright infringers, who are offered a reasonable settlement option versus the legal liability defined in the Digital Millennium Copyrights Act (DMCA). Rightscorp has monetized major media titles via relationships with industry leaders.

In early October, Rightscorp announced plans to further its global expansion with the signing of a consulting agreement with Chinese entrepreneur Mr. Vincent Yen to formalize an agreement with a major Chinese media company, to monitor copyrighted content for online infringement from the world's most populous country, China.

With this agreement, Mr. Yen will assist Rightscorp in securing an exclusive anti-piracy relationship to represent Chinese audio and visual copyrights and monitor peer-to-peer activity in the United States for infringement of Chinese content. Discussions were taking place to bring Rightscorp's technology to China for Chinese and U.S. content.

Furthermore, in October, Rightscorp announced that it secured an agreement with CNLive Culture Media, Inc. CNLive is one of only seven entities licensed by the government to distribute content over mobile devices in the People's Republic of China.

CNLive Culture Media is a culture and media company. It distributes content over mobile devices in the People's Republic of China. CNLive holds the license to distribute content via mobile and IP-enabled devices nationwide. The chief enterprise of CNLive is the distribution of content to internet-connected mobile devices.

This agreement will provide Rightscorp the right to track, enforce, and monetize any of CNLive's programming content being illegally distributed on peer-to-peer platforms within the United States.

Rightscorp, Inc. (RIHT), closed Tuesday's trading session at $0.0169, down 0.59%, on 40,449 volume with 5 trades. The average volume for the last 60 days is 156,716 and the stock's 52-week low/high is $0.0102/$0.055.

Explor Resources, Inc. (EXSFF)

Vantage Wire reported earlier on Explor Resources, Inc. (EXSFF), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Explor Resources, Inc. is a natural resources company whose shares trade on the OTC Markets Group’s OTCQB. The Company has mineral holdings in Ontario, Quebec, Saskatchewan and New Brunswick. Its Flagship project is the Timmins Porcupine West (TPW) Project located in the Porcupine mining camp in Ontario. A gold and base metals exploration company, Explor Resources is based in Rouyn-Noranda, Quebec.

Currently, Explor Resources is centering on exploration in the Abitibi Greenstone Belt. This belt is in both provinces of Ontario and Quebec - around 33 percent in Ontario and 67 percent in Quebec. Explor Resources’ total land position in the Abitibi Greenstone Belt is roughly 25,000 hectares. Furthermore, the Company owns 6,500 hectares of mining claims in New Brunswick.

Abitibi Greenstone Belt properties 100 percent-owned by Explor Resources in Ontario include Carnegie, Kidd Township, Eastford Lake, PG-101, Montrose, Golden Harker, Timmins Porcupine West, and Ogden. Abitibi Greenstone Belt properties 100 percent-owned by Explor Resources in Quebec include East Bay, Nelligan, Destor, and Launay.

In January 2017, Explor Resources announced further results from the 12 Diamond Drill Holes completed on the Chester Copper Property. The Company intersected multiple Copper Zones. Grades are up to 3.65 percent Cu over 5.35 meters on the Chester Copper Property.

The Chester Copper property is in Northumberland County, 70 km southwest of Bathurst, New Brunswick, and 50 km west-northwest of Miramichi, New Brunswick, within the Bathurst Mining Camp. This area has an extensive history in base metal production from VMS deposits.

This past August, Explor Resources announced the results of 8 drill holes being the next series of holes on the diamond drilling program at Timmins Porcupine West. The program consisted of the extension of 5 earlier drilled holes and the completion of 3 new Diamond Drill Holes.

Holes #TPW-17-101EX, #TPW-17-102EX, #17-103EX, #TPW-17-104EX and #TPW-17-109 were extended to test the theory that Shear Zone #5 extended across the property. New Holes #TPW-17-124, #TPW-17-125 and #TPW-17-127 were drilled.

Mr. Chris Dupont, Explor Resources President and Chief Executive Officer, said, "We continue to be extremely pleased and encouraged by these excellent drill results. The fact that Explor continued to intersect near surface gold mineralization in area "B" continue to confirm existence of a near surface open pit gold resource that extends over a strike length of 1800 meters."

Recently, Explor Resources announced that it signed a Memorandum of Understanding (MOU) with the Matachewan First Nation of Matachewan, Ontario and the Mattagami First Nation of Gogama, Ontario, regarding the Montrose Property. The MOU will serve as a framework to govern the relationship between Explor and the First Nations in accordance with their intention of further building a relationship characterized by cooperation and mutual respect, in connection with the development of the Montrose Property.

The Montrose property comprises 20 mining claims (217 units) situated in the Montrose and Midlothian Townships in the Timmins-Porcupine Mining Camp for a total of roughly 3,472 hectares.

Explor Resources, Inc. (EXSFF), closed Tuesday's trading session at $0.0526, even for the day. The average volume for the last 60 days is 17,296 and the stock's 52-week low/high is $0.037/$0.092.

Mentor Capital, Inc. (MNTR)

Stockgoodies, Laissez Faire Today, BUYINS.NET, Stocks That Move, Wealth Insider Alert, Market Intelligence Center Alert, StreetAuthority Daily, Promotion Stock Secrets, InvestorsUnderground, Cancer Roll Up Strategy, Five Star Stock Picks, and Stock Profile reported earlier on Mentor Capital, Inc. (MNTR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mentor Capital, Inc. provides mezzanine financing to leaders in the cannabis arena. The Company looks to come alongside and assist larger private medical marijuana and cannabis companies and their founders in meeting their liquidity, and financial goals, to add protection for investors, and to help incubate private cannabis companies. Listed on the OTCQB, Mentor Capital is headquartered in San Diego, California.

The Company participates in the legal recreational marijuana market. However, its favored focus is medical. The Company looks to facilitate the application of cannabis to cancer wasting, calming seizures, Parkinson’s disease, reducing ocular pressures from glaucoma, in addition to blunting chronic pain.

Mentor Capital transferred to the cannabis space from front-line cancer investments when government actions collapsed the new leading cancer sector. It still retains only minor cancer investments. Mentor will complete the shift to the cannabis market as profitable opportunities to exit present themselves.

Mentor Capital takes a significant position in the diverse members of its portfolio of participating companies. Nevertheless, it leaves operating control in the hands of the cannabis company founders.

Mentor’s preferred involvement is with larger and private pre-IPO (Initial Public Offering) medical marijuana companies that it can help operationally prepare for the public market and finance, sometimes working with institutional partners looking for public liquidity.

Mentor Capital reported in April 2015 that it acquired 100 percent of Cannabis Investor Webcast as the first member of its Public Market Incubator Program. Via its spinoff program, Mentor provides a low-cost option for companies trying to enter the public market.

Mentor Capital announced in March of this year that it took a $1.0 million position in the stock of GW Pharmaceuticals, Plc (GWPH). GW Pharmaceuticals is a United Kingdom (UK) headquartered group developing a portfolio of cannabinoid prescription medicines.

Mentor Capital announced in April 2017 that it initiated funding for its GlauCanna venture for the use of medical marijuana in the treatment of glaucoma patients. The Company will provide funding and business management for any commercial development and holds an 80 percent interest. Dr. Robert M. Mandelkorn (an ophthalmologist specializing in glaucoma) holds 20 percent and provides the medical leadership for the venture.

This past August, Mentor Capital announced that it filed its quarterly Form 10-Q filing for Q2 ended June 30, 2017 with the Securities and Exchange Commission (SEC). For Q2 ended June 30, 2017, the Company had Revenues of $764,549 and Gross Profit of $268,664 with a resulting Net Loss attributable to Mentor of ($258,246) or (1.1 cents) per share. This represents a 15 percent improvement in Revenue from the quarter ended June 30, 2016 Revenues of $667,720 and Gross Profit of $239,313 and a Net Loss of ($287,391) or (1.7 cents) per share.

For the six months ended June 30, 2017 Mentor Capital had Revenues of $1,502,692 and Gross Profit of $532,560 with a resulting Net Loss attributable to Mentor of ($636,857) or (2.9 cents) per share. This represents an improvement over the six months ended June 30, 2016 Revenues of $1,311,013 and Gross Profit of 488,174. The Net Loss for the six months ended June 30, 2016 was ($489,701) or (2.9 cents) per share.

Mentor Capital, Inc. (MNTR), closed Tuesday's trading session at $0.745, down 10.51%, on 90,316 volume with 71 trades. The average volume for the last 60 days is 60,902 and the stock's 52-week low/high is $0.45/$4.82.

GEX Management, Inc. (GXXM)

MarketWatch and OTC Markets reported on GEX Management, Inc. (GXXM), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

GEX Management, Inc. is a licensed Professional Employer Organization (PEO) and a Professional Services Company. It provides complete back office services to its clients in an array of industries. As a PEO, GEX provides HR services for its clients. This includes the payment of wages and taxes, and assisting with state and federal rules and regulation compliance. GEX Management is based in Dallas, Texas. The Company lists on the OTC Markets’ OTCQB.

GEX Management’s services include HR (Human Resources), Payroll, Risk & Compliance Management, Digital Marketing, IT (Information Technology), Executive Consulting, and Accounting/Bookkeeping. The Company uses specially designed technology and a team of professionally trained staff to give clients support and accountability. GEX gives its clients access to technology and systems to set them up for success.

In addition, GEX provides basic bookkeeping services to its clients. This includes Accounts Payable (A/P); Accounts Receivable (A/R); Accounting Manual and Policy Review; Full Service Accounting Services (Bookkeeping); Paperless Workflow System Implementation; and Document Retention. The Company’s staff can perform cash-based or accrual accounting.

GEX Management has engaged NMS Capital Advisors, LLC as its financial advisor. This to explore future growth opportunities for the Company via the capital markets and other strategic initiatives.  With the Agreement, NMS Capital will provide investment banking, financial advisory, as well as broker-dealer services to GEX Management.

GEX Management announced this past June that its Chief Operating Officer (COO), Mrs. Chelsea Christopherson, published an article in Forbes entitled, “How Leaders and Managers Unknowingly Suppress Their Team Members.”  Mrs. Christopherson discusses her personal experiences, and also different situations she has witnessed in which managers suppress, albeit sometimes inadvertently, their own team members. She details these instances in this article. Mrs. Christopherson is one of the youngest women to be an Officer and Director of a public company.

Recently, GEX Management announced the addition of Mr. Andrew Percy, Member of Parliament in the House of Commons of the United Kingdom (UK), and Mr. Jason Bailey, Investment and Business Asset Manager of a private family office, to the GEX Advisory Board team.

Mr. Percy is a three term Member of Parliament in the House of Commons in the UK. Mr. Bailey’s present responsibilities include managing a portfolio of public and private investments, overseeing real-estate investment developments, and day-to-day business logistics.

Last week, GEX Management announced the opening of its Northwest Arkansas regional office. This regional office is next to the Northwest Arkansas Mall. It serves the cities of Springdale, Bentonville, Fayetteville, Rogers and their surrounding communities. The Company’s new office will serve as a local base of operation to work with businesses that are fuelling the present economic growth of Northwest Arkansas.

GEX Management, Inc. (GXXM), closed Tuesday's trading session at $10.25, even for the day. The average volume for the last 60 days is 468 and the stock's 52-week low/high is $1.86/$14.44.

Molori Energy, Inc. (MOLOF)

Streetwise Reports, InvestorsHub, Stockhouse, and MarketWatch reported on Molori Energy, Inc. (MOLOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An oil and gas production company, Molori Energy, Inc. has present operations in the Texas Panhandle West Field. The Company’s operating team, which is based in Borger, Texas, has wide-ranging experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through concentrating on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions. Molori Energy is based in Vancouver, British Columbia.

Currently, the Company owns a 25 percent working interest (WI) in certain leases situated in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC. Molori Energy has 165 producing (PDP) wells as well as an inventory of roughly 202 non-producing wells (PDNP) for a total of 367 wells. The Company is working to RTP (Return To Production) the PDNP wells through performing simple re-works or re-completions.

These assets include low-decline, PDP weighted reserves mainly in the West Panhandle Field of the Hugoton Basin of Texas. These assets are about 50 percent oil and 50 percent liquid rich gas (HIGH BTU premium gas) principally situated in Carson, Gray, and Hutchinson Counties of District 10.

Molori Energy’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to produce steady cash flows. Over 60 wells have been reactivated so far. These are producing from the prolific Brown Dolomite formation.

Molori Energy and Ponderosa Energy have identified a development opportunity in the Red Cave formation. This formation is common throughout its leases at a shallower depth of 2,100’ to 2,300’. Improved fracing technologies and completion techniques have shown the Red Cave to be an economic development target.

Last month, Molori Energy announced the signing of a definitive agreement to purchase an additional 25 percent WI in certain oil and gas leases from its Texas-based operating partner, Ponderosa Energy. This latest acquisition, combined with the 25 percent interest the Company currently has in these same leases, will bring Molori Energy's overall interest to 50 percent.

In addition, last month, Molori Energy announced the signing of a definitive agreement to secure a 75 percent WI in certain oil and gas leases, known formally as the "Red Cave Leases" in District 10, Texas. This acquisition of these leases, encompassing 11,000 acres with access to Red Cave, and with access to other formations, is an important milestone of Phase 1 of Molori Energy's development plan.

Mr. Joel Dumaresq, Molori Energy’s Chief Executive Officer, said, "The acquisition of this expansive land package is the result of many months of work, evaluation and negotiation. With the recent commercial success of the M1 Well on our existing acreage, we have decided to focus our exploration efforts and capital on this prospective new acreage as its sheer size provides us with the greatest opportunity to add significantly to our reserves."

Molori Energy, Inc. (MOLOF), closed Tuesday's trading session at $0.3307, up 1.13%, on 33,150 volume with 21 trades. The average volume for the last 60 days is 62,368 and the stock's 52-week low/high is $0.05/$0.52.

CV Sciences, Inc. (CVSI)

OTCtipReporter, Penny Picks, PennyStockScholar, Profitable Trader Authority, Promotion Stock Secrets, Wealth Insider Alert, Market Intelligence Center Alert, StreetAuthority Daily, Wall Street Mover, Damn Good Penny Picks, and Stock Commander reported previously on CV Sciences, Inc. (CVSI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

CV Sciences, Inc. centers on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). A life science company, it operates two divisions - Pharmaceuticals and Consumer Products. These divisions are supported by its medical and scientific advisory board, and state‐of‐the art production facilities. CV Sciences lists on the OTCQB.

The Company previously went by the name CannaVEST Corp. It changed its name to CV Sciences, Inc. in January 2016. CV Sciences has main offices and facilities in San Diego, California and Las Vegas, Nevada.

The Company’s Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Each consumer products brand is backed by a formal safety review, an increasing body of case reports, and physician’s recommendations. Furthermore, CV Sciences manufactures, markets, and sells plant-based CBD products under the PlusCBD brand. This is for a variety of market sectors. These include nutraceutical, beauty care, specialty foods, and also vape.

CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine. It is pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications using cannabidiol as the active pharmaceutical ingredient. The Company has attained promising preclinical results in the development of cannabinoid medicines for the treatment of an array of medical conditions.

CV Sciences acquired CanX, Inc. in December 2015. CanX is a Pre-Clinical drug development company. It is concentrating on significant unmet medical needs. CanX’s initial drug candidate is CVSI-007. CVSI-007 chewing gum combines CBD and Nicotine. It is patent pending. CVSI-007 is a proprietary chewing gum. It combines synthetic CBD and nicotine to effectively treat smokeless tobacco addiction.

CV Sciences drug development efforts include pursuing synthetic-based Cannabidiol (CBD) drug candidates in areas that have the potential to provide important improvements in therapeutic patient treatments with significant addressable markets.

The Company’s consumer products division has its Purified Liquids™ (high quality, premium CBD vape e-liquids). The launch of this brand targets the increasing vape industry. Purified Liquids™ is made from 99.9 percent CBD from hemp-derived crystals. It contains 0 percent THC.

This past September, CV Sciences commented on the latest research citing Cannabidiol in lessening the risk of Post-Traumatic Stress Disorder (PTSD). The Company highlighted another study identifying additional therapeutic opportunities of cannabidiol (CBD) that include the potential to prevent PTSD.

Researchers at the Federal University of Parana, Santa Catarina, and the University of Sao Paulo, have preclinical evidence that when given immediately after a fearful event, CBD can considerably decrease the conditioned fear expression and fear generalization and the relative resistance to extinction of the fear memory. These findings have important implications for the possible role of CBD in reducing PTSD.

CV Sciences is scheduled to host a conference call to discuss its Q3 2017 results at 1:15 pm PT/4:15pm ET on Wednesday, November 8, 2017. The Company’s Chief Financial Officer (CFO), Mr. Joseph Dowling, will lead the call to provide an operational and financial summary of CV Sciences’ Q3 of 2017.

CV Sciences, Inc. (CVSI), closed Tuesday's trading session at $0.25, up 10.38%, on 711,016 volume with 178 trades. The average volume for the last 60 days is 308,106 and the stock's 52-week low/high is $0.136/$0.72.


The QualityStocks
Company Corner


InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.3883, up 7.86%, on 1,068,484 volume with 493 trades. The stock’s average daily volume over the past 60 days is 506,262, and its 52-week low/high is $0.09/$0.72.

NetworkNewsWire Editorial Coverage: Morgan Stanley’s research team in January 2017 forecast that biotech-pharmaceutical companies – with a combined $75 billion in cash on hand – would strategize to boost revenue growth through mergers and acquisitions of smaller companies with high-potential product pipelines (http://nnw.fm/mN24x). Growth via strategic acquisition makes more sense to cost-conscious Big Pharma than does shelling out $2.55 billion (http://nnw.fm/3Qr3S) to develop a new drug in-house. With growing interest in the convergence of cannabis and medicine, companies like InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), which has an innovative biosynthesis technology that addresses the regulatory concerns associated with consistent pharmaceutical-grade cannabinoids and logistical constraints on development, may find themselves on the radar of Big Pharma.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Biotech M&A Momentum Attractive for Cannabinoid R&D Space

CFN Media Exclusive CEO Interview: InMed Pharmaceuticals' Biosynthesis Platform Results in an Industry First

NetworkNewsWire Announces Publication Discussing Companies Developing Novel Methods of Extracting Medicinal-Grade Cannabinoids

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0171, off by 5.00%, on 1,479,512 volume with 82 trades. The stock’s average daily volume over the past 60 days is 3,134,610, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (GOHE) is pleased to announce that in recent weeks it has been focused on ramping-up sales, marketing, and networking efforts to facilitate the acquisition of new clients and strategic partnerships in the fast-growing logistics industry.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. is in the Process of Exploring New Partnerships to Take Advantage of the Fast-Growing Logistics Industry

MoneyTrac Technology, Inc. Sells Front Cover of PotSaver’s Premier Los Angeles Edition

Global Payout’s MoneyTrac Technology, Inc. Co-Hosts Finance and Technology Networking Event for the Cannabis Industry

Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.16653, off by 1.93%, on 64,723 volume with 25 trades. The stock’s average daily volume over the past 60 days is 79,078 and its 52-week low/high is $0.0711/$0.2419.

The recent surge in Chinese mobile gaming is also impacting the U.S. gaming market where mobile game stocks are seeing a boost. One smaller company that’s been able to position itself alongside the giants is New York-based mobile gamer Tapinator, Inc. (OTC: TAPM). The company has announced several new titles this year and has seen solid results from its mix of low-cost development and potential for blockbuster type game franchises. Tapinator is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

Chinese Mobile Gaming Surge Helps Boost U.S. Mobile Gaming Companies

Tapinator Announces Publishing Partnership with Robot Cake Games

Tapinator, Inc. (TAPM) Engages NetworkNewsWire for Corporate Communications Solutions


The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $0.56, up 12.00%, on 33,002 volume with 52 trades. The stock’s average daily volume over the past 60 days is 16,984, and its 52-week low/high is $0.49/$4.89.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO, Inc. Expands Testing Services at its Northern California Laboratory

EVIO Labs Expands to Fifth Oregon Location

EVIO Labs Sees Demand for Testing Services Double

Greenkraft, Inc. (GKIT)

The QualityStocks Daily Newsletter would like to spotlight Greenkraft, Inc. (GKIT). Today, Greenkraft, Inc. closed trading at $0.096588, up 27.76%, on 187 volume with 2 trades. The stock’s average daily volume over the past 60 days is 10,335 and its 52-week low/high is $0.02/$0.20.

Greenkraft, Inc. (GKIT) is a nationally recognized company specializing in the production of alternative fuel automotive products, including engines and commercial trucks. Located in Santa Ana, California, the company's mission is to provide clean, green, energy efficient automotive products that have a price advantage coupled with unparalleled American performance. Established in 2008, Greenkraft, Inc. serves the commercial truck market powered by the alternative fuels CNG and LPG in classes 4, 5, 6 and 7.

Greenkraft's new line of trucks, known as the G3 and G4, will accommodate weights of 26,000 lbs. and 33,000 lbs., respectively. George Gemayel, CEO of Greenkraft, Inc., said the demand for larger trucks that run on alternative fuels continues to increase.

"Greenkraft is going to revolutionize the trucking industry with these new 26,000 and 33,000 lbs. trucks that run on CNG and PROPANE fuel," Gemayel states in a press release. "The only way we can meet increased demand for Greenkraft products is to expand our current factory. This expansion is one of many factors that will substantially increase the Company's revenue in 2017."

Greenkraft produces a cab forward design for its commercial trucks, which allows the passenger area to be much larger than in other similar sized vehicles. Several tank capacity options exist, making it easy to select the most efficient model for a client's specific needs. Greenkraft is one of the only companies in the world to offer a refrigeration option with an alternative fuel truck – an essential, must-have option for many businesses.

Greenkraft trucks, considered among the best performing in the heavy-duty market, are used in a variety of industries and in some of the nation's largest cities. The company also offers a line of trucks designed to run with a package from Allison Transmission Holdings, Inc. (NYSE: ALSN), which gives clients the option of purchasing a fully automatic transmission vehicle. This option expands the size of the driver pool since fully automatic shifting reduces driver fatigue, contributes to solving the issue of driver retention, and it is easy to use.

CNG and LPG conversion systems made by Greenkraft are available for several major automobile brands including Ford, GM and Isuzu/GM. Installation, service, parts and warranty are all available through Greenkraft facilities and its partners. Disclaimer

Greenkraft, Inc. Blog

Greenkraft, Inc. News:

Greenkraft, Inc. (OTCQB: GKIT) Signs Supply Contracts for its Alternative Fuel Commercial Trucks, Rising to Meet Industry Demand

Greenkraft, Inc.'s (GKIT) Alternative Fuel Engine Awarded Certification for Exceeding California's Clean Air Act Standards

Greenkraft, Inc. Expands Distribution Network to Meet Increased Product Demand

Cache Elite Inc. (ILUS)

The QualityStocks Daily Newsletter would like to spotlight Cache Elite Inc. (ILUS). Today, Cache Elite Inc. closed trading at $0.009, up 9.76%, on 253,546 volume with 10 trades. The stock’s average daily volume over the past 60 days is 215,490 and its 52-week low/high is $0.0021/$0.065.

Cache Elite Inc. (ILUS) is a forward-thinking technology and service provider. The company provides homeowners with the latest in 3D designs, decorative hardware (http://www.eliteknobs.com), and travel and vacation services. Its foray into travel-related services can be found at the TripWitz website (http://www.tripwitz.com) where its proprietary back-end software, called Internet Travel Management Software, helps TripWitz provide its customers with a distinctive, cost-effective and perfect travel experience that sets it apart from other online travel agencies such as Expedia and Travelocity.

TripWitz provides real-time, dynamically packaged vacation quotes that include airfare, hotels, villas, ground transportation and activities. Every client searching for a smarter way to travel will find TripWitz is able to cut out the stress and frustrations found with other online travel agents. The company provides its intuitive travel services to clients searching vacations possibilities at more than 20,000 destinations around the globe.

TripWitz contracts with over 500,000 hotels and connects with the world's airlines through Google's ITA Gateway software that allows for advanced availability solutions to satisfy millions of queries per second at the lowest possible fares. Seasonal rate fluctuations for many travel services, including ground transportation options, are included in the company's software, giving clients the best possible rates. TripWitz prides itself on giving users a friendly vacation experience that includes access to an experienced vacation destination specialist. Customers are never left to fend for themselves at any point of their vacation experience. TripWitz is also accepting Bitcoins, the international cryptocurrency, as payment for not only flights but vacations as well.

A new report published by Allied Market Research projects the global online travel market will reach an estimated $1,091 billion by 2022, with the Asia-Pacific region expected to witness the highest growth during the forecast period. Travelers are looking for sound help in making travel decisions that fit within their budgets. Younger travelers, those within the 21-31 year age bracket, are seen as a more mobile generation, using social media and smartphones for many of their travel planning and booking needs.

TripWitz is an accredited member of the CCRA (Travel Commerce Network), which connects the company to over 180,000 properties worldwide. TripWitz is also an ARC approval agency. ARC accredited agencies are the most select group of dedicated professionals in the U.S. travel industry and are recognized as having met stringent financial, personnel and security requirements.

The official press release announcing the recent launch of TripWitz can be found at the following link: Cache Elite Inc. (ILUS) Unveils New Venture Into the $341 Billion Travel Industry. Disclaimer

Cache Elite Inc. Blog

Cache Elite Inc. News:

Cache Elite Inc. (ILUS) Engages NetworkNewsWire for Corporate Communications Solutions

Cache Elite Inc. (ILUS) is “One to Watch”

A New Audio Interview with Cache Elite, Inc. CEO, Derrick McWilliams, is now at SmallCapVoice.com


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.7849, up 5.91%, on 419,522 volume with 227 trades. The stock’s average daily volume over the past 60 days is 277,880 and its 52-week low/high is $0.6171/$1.25.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Appoints New Independent Chair

NetworkNewsWire Announces Publication Highlighting Public Companies Set to Reap the Rewards of the Cannabis Sector's Continuous Growth

NetworkNewsWire Announces Publication Discussing How Licensed Canadian Cannabis Producers are Preparing for Industry Forecasts


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



MarketClub Analysis
(MYO) +108.73%


(ARSC) +60.87%


CFN Media Group
(NINE.V) +28.44%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251